Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) Stock Competitors & Peer Comparison
See KNSA's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for KNSA and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| KNSA | $79.78 | +2.33% | 6B | 81.19 | $0.97 | N/A |
| RPRX | $56.93 | +0.30% | 24.9B | 10.71 | $5.25 | +1.63% |
| CORT | $121.19 | +1.33% | 12.8B | 338.69 | $0.35 | N/A |
| WBA | $11.98 | +0.50% | 10.4B | -1.64 | -$7.29 | +4.17% |
| LQDA | $27.38 | +2.62% | 2.5B | 20.45 | $1.37 | N/A |
| PBH | $48.23 | +1.39% | 2.3B | 10.82 | $4.42 | N/A |
| HROWL | $25.61 | +0.19% | 1.4B | N/A | N/A | N/A |
| HROWM | $26.03 | -0.08% | 1.3B | N/A | N/A | N/A |
| LTGO | $16.00 | +3.09% | 889.7M | -5.87 | -$2.52 | N/A |
| HELP | $11.80 | +12.27% | 664.5M | -2.57 | -$4.16 | N/A |
Stock Comparison
Royalty Pharma plc (NASDAQ: RPRX)
KNSA vs RPRX Comparison October 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6B. In comparison, RPRX has a market cap of 24.9B. Regarding current trading prices, KNSA is priced at $79.78 on the NASDAQ, while RPRX trades at $56.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 81.19, whereas RPRX's P/E ratio is 10.71. In terms of profitability, KNSA's ROE is +0.14%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, KNSA is more volatile compared to RPRX. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check RPRX's competition here
Corcept Therapeutics Incorporated (NASDAQ: CORT)
KNSA vs CORT Comparison October 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6B. In comparison, CORT has a market cap of 12.8B. Regarding current trading prices, KNSA is priced at $79.78 on the NASDAQ, while CORT trades at $121.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 81.19, whereas CORT's P/E ratio is 338.69. In terms of profitability, KNSA's ROE is +0.14%, compared to CORT's ROE of +0.08%. Regarding short-term risk, KNSA is less volatile compared to CORT. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check CORT's competition here
Walgreens Boots Alliance, Inc. (NASDAQ: WBA)
KNSA vs WBA Comparison October 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6B. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, KNSA is priced at $79.78 on the NASDAQ, while WBA trades at $11.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 81.19, whereas WBA's P/E ratio is -1.64. In terms of profitability, KNSA's ROE is +0.14%, compared to WBA's ROE of -0.57%. Regarding short-term risk, KNSA is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check WBA's competition here
Liquidia Corporation (NASDAQ: LQDA)
KNSA vs LQDA Comparison October 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6B. In comparison, LQDA has a market cap of 2.5B. Regarding current trading prices, KNSA is priced at $79.78 on the NASDAQ, while LQDA trades at $27.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 81.19, whereas LQDA's P/E ratio is 20.45. In terms of profitability, KNSA's ROE is +0.14%, compared to LQDA's ROE of +1.50%. Regarding short-term risk, KNSA is less volatile compared to LQDA. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check LQDA's competition here
Prestige Consumer Healthcare Inc. (NYSE: PBH)
KNSA vs PBH Comparison October 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6B. In comparison, PBH has a market cap of 2.3B. Regarding current trading prices, KNSA is priced at $79.78 on the NASDAQ, while PBH trades at $48.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 81.19, whereas PBH's P/E ratio is 10.82. In terms of profitability, KNSA's ROE is +0.14%, compared to PBH's ROE of +0.09%. Regarding short-term risk, KNSA is more volatile compared to PBH. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check PBH's competition here
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL)
KNSA vs HROWL Comparison October 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6B. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, KNSA is priced at $79.78 on the NASDAQ, while HROWL trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 81.19, whereas HROWL's P/E ratio is N/A. In terms of profitability, KNSA's ROE is +0.14%, compared to HROWL's ROE of -1.04%. Regarding short-term risk, KNSA is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check HROWL's competition here
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM)
KNSA vs HROWM Comparison October 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6B. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, KNSA is priced at $79.78 on the NASDAQ, while HROWM trades at $26.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 81.19, whereas HROWM's P/E ratio is N/A. In terms of profitability, KNSA's ROE is +0.14%, compared to HROWM's ROE of -1.04%. Regarding short-term risk, KNSA is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check HROWM's competition here
Latigo Biotherapeutics Inc. (NASDAQ: LTGO)
KNSA vs LTGO Comparison October 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6B. In comparison, LTGO has a market cap of 889.7M. Regarding current trading prices, KNSA is priced at $79.78 on the NASDAQ, while LTGO trades at $16.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 81.19, whereas LTGO's P/E ratio is -5.87. In terms of profitability, KNSA's ROE is +0.14%, compared to LTGO's ROE of N/A. Regarding short-term risk, KNSA is less volatile compared to LTGO. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check LTGO's competition here
Helus Pharma Inc. (NASDAQ: HELP)
KNSA vs HELP Comparison October 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6B. In comparison, HELP has a market cap of 664.5M. Regarding current trading prices, KNSA is priced at $79.78 on the NASDAQ, while HELP trades at $11.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 81.19, whereas HELP's P/E ratio is -2.57. In terms of profitability, KNSA's ROE is +0.14%, compared to HELP's ROE of -0.71%. Regarding short-term risk, KNSA is less volatile compared to HELP. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check HELP's competition here
Sinovac Biotech Ltd. (NASDAQ: SVA)
KNSA vs SVA Comparison October 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6B. In comparison, SVA has a market cap of 464.9M. Regarding current trading prices, KNSA is priced at $79.78 on the NASDAQ, while SVA trades at $6.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 81.19, whereas SVA's P/E ratio is -5.68. In terms of profitability, KNSA's ROE is +0.14%, compared to SVA's ROE of -0.01%. Regarding short-term risk, KNSA is more volatile compared to SVA. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check SVA's competition here
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL)
KNSA vs CUVL Comparison October 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6B. In comparison, CUVL has a market cap of 281.4M. Regarding current trading prices, KNSA is priced at $79.78 on the NASDAQ, while CUVL trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 81.19, whereas CUVL's P/E ratio is 12.04. In terms of profitability, KNSA's ROE is +0.14%, compared to CUVL's ROE of N/A. Regarding short-term risk, KNSA is more volatile compared to CUVL. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check CUVL's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
KNSA vs CELG-RI Comparison October 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6B. In comparison, CELG-RI has a market cap of 233.9M. Regarding current trading prices, KNSA is priced at $79.78 on the NASDAQ, while CELG-RI trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 81.19, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, KNSA's ROE is +0.14%, compared to CELG-RI's ROE of N/A. Regarding short-term risk, KNSA is less volatile compared to CELG-RI. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check CELG-RI's competition here
High Tide Inc. (NASDAQ: HITI)
KNSA vs HITI Comparison October 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6B. In comparison, HITI has a market cap of 226.7M. Regarding current trading prices, KNSA is priced at $79.78 on the NASDAQ, while HITI trades at $2.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 81.19, whereas HITI's P/E ratio is -9.53. In terms of profitability, KNSA's ROE is +0.14%, compared to HITI's ROE of -0.36%. Regarding short-term risk, KNSA is more volatile compared to HITI. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check HITI's competition here
Electra Therapeutics Inc. (NASDAQ: ETRA)
KNSA vs ETRA Comparison October 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6B. In comparison, ETRA has a market cap of 193.9M. Regarding current trading prices, KNSA is priced at $79.78 on the NASDAQ, while ETRA trades at $9.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 81.19, whereas ETRA's P/E ratio is -3.45. In terms of profitability, KNSA's ROE is +0.14%, compared to ETRA's ROE of N/A. Regarding short-term risk, KNSA is less volatile compared to ETRA. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check ETRA's competition here
Citius Oncology, Inc. (NASDAQ: CTOR)
KNSA vs CTOR Comparison October 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6B. In comparison, CTOR has a market cap of 78.9M. Regarding current trading prices, KNSA is priced at $79.78 on the NASDAQ, while CTOR trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 81.19, whereas CTOR's P/E ratio is -1.81. In terms of profitability, KNSA's ROE is +0.14%, compared to CTOR's ROE of -1.03%. Regarding short-term risk, KNSA is less volatile compared to CTOR. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check CTOR's competition here
Atlantic International Corp. (NASDAQ: ATLN)
KNSA vs ATLN Comparison October 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6B. In comparison, ATLN has a market cap of 73.2M. Regarding current trading prices, KNSA is priced at $79.78 on the NASDAQ, while ATLN trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 81.19, whereas ATLN's P/E ratio is -0.68. In terms of profitability, KNSA's ROE is +0.14%, compared to ATLN's ROE of -83.20%. Regarding short-term risk, KNSA is less volatile compared to ATLN. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check ATLN's competition here
Rite Aid Corporation (NYSE: RAD)
KNSA vs RAD Comparison October 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6B. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, KNSA is priced at $79.78 on the NASDAQ, while RAD trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 81.19, whereas RAD's P/E ratio is -0.05. In terms of profitability, KNSA's ROE is +0.14%, compared to RAD's ROE of +2.76%. Regarding short-term risk, KNSA is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check RAD's competition here
Damora Therapeutics, Inc. (NASDAQ: GLTO)
KNSA vs GLTO Comparison October 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6B. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, KNSA is priced at $79.78 on the NASDAQ, while GLTO trades at $21.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 81.19, whereas GLTO's P/E ratio is -1.78. In terms of profitability, KNSA's ROE is +0.14%, compared to GLTO's ROE of -0.83%. Regarding short-term risk, KNSA is less volatile compared to GLTO. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check GLTO's competition here
Nasus Pharma Ltd. (AMEX: NSRX)
KNSA vs NSRX Comparison October 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6B. In comparison, NSRX has a market cap of 30.9M. Regarding current trading prices, KNSA is priced at $79.78 on the NASDAQ, while NSRX trades at $3.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 81.19, whereas NSRX's P/E ratio is -4.99. In terms of profitability, KNSA's ROE is +0.14%, compared to NSRX's ROE of -1.59%. Regarding short-term risk, KNSA is less volatile compared to NSRX. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check NSRX's competition here
SCYNEXIS, Inc. (NASDAQ: SCYX)
KNSA vs SCYX Comparison October 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6B. In comparison, SCYX has a market cap of 26.5M. Regarding current trading prices, KNSA is priced at $79.78 on the NASDAQ, while SCYX trades at $4.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 81.19, whereas SCYX's P/E ratio is -1.23. In terms of profitability, KNSA's ROE is +0.14%, compared to SCYX's ROE of -0.21%. Regarding short-term risk, KNSA is less volatile compared to SCYX. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check SCYX's competition here
Cosmos Health Inc. (NASDAQ: COSM)
KNSA vs COSM Comparison October 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6B. In comparison, COSM has a market cap of 17.1M. Regarding current trading prices, KNSA is priced at $79.78 on the NASDAQ, while COSM trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 81.19, whereas COSM's P/E ratio is -0.43. In terms of profitability, KNSA's ROE is +0.14%, compared to COSM's ROE of -1.19%. Regarding short-term risk, KNSA is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check COSM's competition here
Cerenome, Inc. (NASDAQ: CNSY)
KNSA vs CNSY Comparison October 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6B. In comparison, CNSY has a market cap of 12.3M. Regarding current trading prices, KNSA is priced at $79.78 on the NASDAQ, while CNSY trades at $1.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 81.19, whereas CNSY's P/E ratio is -0.43. In terms of profitability, KNSA's ROE is +0.14%, compared to CNSY's ROE of -3.94%. Regarding short-term risk, KNSA is less volatile compared to CNSY. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check CNSY's competition here
Biofrontera Inc. (NASDAQ: BFRI)
KNSA vs BFRI Comparison October 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6B. In comparison, BFRI has a market cap of 11.8M. Regarding current trading prices, KNSA is priced at $79.78 on the NASDAQ, while BFRI trades at $0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 81.19, whereas BFRI's P/E ratio is -1.67. In terms of profitability, KNSA's ROE is +0.14%, compared to BFRI's ROE of -1.28%. Regarding short-term risk, KNSA is less volatile compared to BFRI. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check BFRI's competition here
China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD)
KNSA vs CJJD Comparison October 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6B. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, KNSA is priced at $79.78 on the NASDAQ, while CJJD trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 81.19, whereas CJJD's P/E ratio is -0.46. In terms of profitability, KNSA's ROE is +0.14%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, KNSA is less volatile compared to CJJD. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check CJJD's competition here
SunLink Health Systems, Inc. (AMEX: SSY)
KNSA vs SSY Comparison October 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6B. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, KNSA is priced at $79.78 on the NASDAQ, while SSY trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 81.19, whereas SSY's P/E ratio is -2.86. In terms of profitability, KNSA's ROE is +0.14%, compared to SSY's ROE of -0.09%. Regarding short-term risk, KNSA is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check SSY's competition here
Scienture Holdings, Inc. (NASDAQ: SCNX)
KNSA vs SCNX Comparison October 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6B. In comparison, SCNX has a market cap of 6.3M. Regarding current trading prices, KNSA is priced at $79.78 on the NASDAQ, while SCNX trades at $3.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 81.19, whereas SCNX's P/E ratio is -1.84. In terms of profitability, KNSA's ROE is +0.14%, compared to SCNX's ROE of -0.54%. Regarding short-term risk, KNSA is less volatile compared to SCNX. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check SCNX's competition here
POMDOCTOR Ltd (NASDAQ: POM)
KNSA vs POM Comparison October 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6B. In comparison, POM has a market cap of 5.4M. Regarding current trading prices, KNSA is priced at $79.78 on the NASDAQ, while POM trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 81.19, whereas POM's P/E ratio is -0.11. In terms of profitability, KNSA's ROE is +0.14%, compared to POM's ROE of +0.16%. Regarding short-term risk, KNSA is less volatile compared to POM. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check POM's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMS)
KNSA vs BGMS Comparison October 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6B. In comparison, BGMS has a market cap of 4.5M. Regarding current trading prices, KNSA is priced at $79.78 on the NASDAQ, while BGMS trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 81.19, whereas BGMS's P/E ratio is -0.23. In terms of profitability, KNSA's ROE is +0.14%, compared to BGMS's ROE of -0.32%. Regarding short-term risk, KNSA is less volatile compared to BGMS. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check BGMS's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
KNSA vs BFRIW Comparison October 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6B. In comparison, BFRIW has a market cap of 4.3M. Regarding current trading prices, KNSA is priced at $79.78 on the NASDAQ, while BFRIW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 81.19, whereas BFRIW's P/E ratio is -0.01. In terms of profitability, KNSA's ROE is +0.14%, compared to BFRIW's ROE of -1.28%. Regarding short-term risk, KNSA is less volatile compared to BFRIW. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check BFRIW's competition here
Eocene Ltd. (NASDAQ: EOCN)
KNSA vs EOCN Comparison October 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6B. In comparison, EOCN has a market cap of 3.8M. Regarding current trading prices, KNSA is priced at $79.78 on the NASDAQ, while EOCN trades at $3.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 81.19, whereas EOCN's P/E ratio is -0.26. In terms of profitability, KNSA's ROE is +0.14%, compared to EOCN's ROE of N/A. Regarding short-term risk, KNSA is less volatile compared to EOCN. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check EOCN's competition here
Paranovus Entertainment Technology Ltd. (NASDAQ: PAVS)
KNSA vs PAVS Comparison October 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6B. In comparison, PAVS has a market cap of 3.1M. Regarding current trading prices, KNSA is priced at $79.78 on the NASDAQ, while PAVS trades at $3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 81.19, whereas PAVS's P/E ratio is -0.04. In terms of profitability, KNSA's ROE is +0.14%, compared to PAVS's ROE of -0.46%. Regarding short-term risk, KNSA is less volatile compared to PAVS. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check PAVS's competition here
MedAvail Holdings, Inc. (NASDAQ: MDVL)
KNSA vs MDVL Comparison October 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6B. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, KNSA is priced at $79.78 on the NASDAQ, while MDVL trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 81.19, whereas MDVL's P/E ratio is -0.05. In terms of profitability, KNSA's ROE is +0.14%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, KNSA is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check MDVL's competition here
ETHZilla Corporation Warrant (NASDAQ: ATNFW)
KNSA vs ATNFW Comparison October 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6B. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, KNSA is priced at $79.78 on the NASDAQ, while ATNFW trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 81.19, whereas ATNFW's P/E ratio is N/A. In terms of profitability, KNSA's ROE is +0.14%, compared to ATNFW's ROE of -2.15%. Regarding short-term risk, KNSA is less volatile compared to ATNFW. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check ATNFW's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMSP)
KNSA vs BGMSP Comparison October 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6B. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, KNSA is priced at $79.78 on the NASDAQ, while BGMSP trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 81.19, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, KNSA's ROE is +0.14%, compared to BGMSP's ROE of -0.32%. Regarding short-term risk, KNSA is less volatile compared to BGMSP. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check BGMSP's competition here
AstraZeneca PLC ADRhedged (AMEX: AZNH)
KNSA vs AZNH Comparison October 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6B. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, KNSA is priced at $79.78 on the NASDAQ, while AZNH trades at $53.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 81.19, whereas AZNH's P/E ratio is 38.35. In terms of profitability, KNSA's ROE is +0.14%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, KNSA is more volatile compared to AZNH. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check AZNH's competition here
Leafly Holdings, Inc. (NASDAQ: LFLYW)
KNSA vs LFLYW Comparison October 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6B. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, KNSA is priced at $79.78 on the NASDAQ, while LFLYW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 81.19, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, KNSA's ROE is +0.14%, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, KNSA is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check LFLYW's competition here
ProPhase Labs, Inc. (NASDAQ: PRPH)
KNSA vs PRPH Comparison October 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6B. In comparison, PRPH has a market cap of 140.2K. Regarding current trading prices, KNSA is priced at $79.78 on the NASDAQ, while PRPH trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 81.19, whereas PRPH's P/E ratio is N/A. In terms of profitability, KNSA's ROE is +0.14%, compared to PRPH's ROE of -13.59%. Regarding short-term risk, KNSA is less volatile compared to PRPH. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check PRPH's competition here
Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD)
KNSA vs CPD Comparison October 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6B. In comparison, CPD has a market cap of 0. Regarding current trading prices, KNSA is priced at $79.78 on the NASDAQ, while CPD trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 81.19, whereas CPD's P/E ratio is N/A. In terms of profitability, KNSA's ROE is +0.14%, compared to CPD's ROE of N/A. Regarding short-term risk, KNSA is more volatile compared to CPD. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check CPD's competition here
Express Scripts Holding Company (NASDAQ: ESRX)
KNSA vs ESRX Comparison October 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6B. In comparison, ESRX has a market cap of 0. Regarding current trading prices, KNSA is priced at $79.78 on the NASDAQ, while ESRX trades at $92.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 81.19, whereas ESRX's P/E ratio is 10.69. In terms of profitability, KNSA's ROE is +0.14%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, KNSA is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check ESRX's competition here
Impax Laboratories, Inc. (NASDAQ: IPXL)
KNSA vs IPXL Comparison October 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6B. In comparison, IPXL has a market cap of 0. Regarding current trading prices, KNSA is priced at $79.78 on the NASDAQ, while IPXL trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 81.19, whereas IPXL's P/E ratio is -10.11. In terms of profitability, KNSA's ROE is +0.14%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, KNSA is less volatile compared to IPXL. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check IPXL's competition here
Orexigen Therapeutics, Inc. (NASDAQ: OREX)
KNSA vs OREX Comparison October 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6B. In comparison, OREX has a market cap of 0. Regarding current trading prices, KNSA is priced at $79.78 on the NASDAQ, while OREX trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 81.19, whereas OREX's P/E ratio is -0.14. In terms of profitability, KNSA's ROE is +0.14%, compared to OREX's ROE of -0.54%. Regarding short-term risk, KNSA is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check OREX's competition here
POZEN Inc. (NASDAQ: POZN)
KNSA vs POZN Comparison October 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6B. In comparison, POZN has a market cap of 0. Regarding current trading prices, KNSA is priced at $79.78 on the NASDAQ, while POZN trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 81.19, whereas POZN's P/E ratio is N/A. In terms of profitability, KNSA's ROE is +0.14%, compared to POZN's ROE of +0.61%. Regarding short-term risk, KNSA is less volatile compared to POZN. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check POZN's competition here
Shire plc (NASDAQ: SHPG)
KNSA vs SHPG Comparison October 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6B. In comparison, SHPG has a market cap of 0. Regarding current trading prices, KNSA is priced at $79.78 on the NASDAQ, while SHPG trades at $179.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 81.19, whereas SHPG's P/E ratio is 11.35. In terms of profitability, KNSA's ROE is +0.14%, compared to SHPG's ROE of +0.13%. Regarding short-term risk, KNSA is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check SHPG's competition here